The FDA Wants To Hear From You About Marijuana Scheduling

Generic 11 April 2018 | 0 Comments

…At least that’s how the public comment process works.  This year, the United Nations World Health Organization is due to review the current international classification of marijuana, THC, cannabidiol, and other related compounds and preparations this year. In the lead-up, the WHO is asking member nations submit feedback, of which no nation is more influential than the [...]

Tagged in , , ,

Congressional Lawmakers Demand The VA Study Medical Marijuana

Generic 30 October 2017 | 0 Comments

Members of the US House Committee on Veteran’s Affairs are demanding the Department of Veterans Affairs facilitate protocols to assess the efficacy of medical cannabis in veterans suffering from chronic pain and post-traumatic stress. Minnesota Democrat Tim Walz, along with nine other Democrat members of the Committee, authored an October 26, 2017 letter to VA [...]

Tagged in , , ,

FDA Seeking Public Comments On CBD

Generic 30 August 2017 | 0 Comments

On Regulations.Gov, right now, the Federal Food and Drug Administration (FDA) is soliciting public comments with regard to the therapeutic utility and abuse liability of various controlled substances, including cannabidiol (CBD). The agency will consider these comments prior to preparing a formal response to the World Health Organization, which is considering placing the substances within their [...]

Tagged in , ,

Medical Marijuana Research Act of 2017

Generic 17 August 2017 | 0 Comments

Representatives Andy Harris, M.D. (R-MD-01), Earl Blumenauer (D-OR-03), H. Morgan Griffith (R-VA-09), and Zoe Lofgren (D-CA-19) introduced H.R. 3391: The Medical Marijuana Research Act of 2017. This Act amends the federal law to facilitate clinical investigations involving the use of cannabis and cannabis-derived products. As you may know, there are many benefits to medical cannabis. [...]

Tagged in ,

DEA Reaffirms Stance That CBD Meets Schedule I Criteria — Reality Says Otherwise

Generic 11 July 2017 | 0 Comments

The US Drug Enforcement Administration has publicly reiterated its position that cannabidiol, a non-psychotropic cannabinoid, is properly categorized under federal law as a schedule I controlled substance — meaning that, by definition, it possesses “a high potential for abuse,” “no currently accepted medical use in treatment in the United States,” and lacks “accepted safety … [...]

Tagged in , , ,